HAGA.BIO has successfully raised SEK 20.9 million in an oversubscribed financing round, providing new resources to accelerate product development, commercialisation, and collaborations with both academia and industry.
Founded in 2024, the Stockholm-based company is developing technologies designed to bridge the gap between the discovery of spatial RNA biomarkers and their clinical application. By enabling scalable and cost-effective validation workflows, HAGA.BIO aims to help researchers and healthcare innovators translate promising discoveries into practical tools that can ultimately benefit patients.
The financing round was led by Almi Invest, Life Science Invest and SU Ventures, together with a group of private investors and industry experts. Combined with previous funding, the company has now raised close to USD 3 million (approximately SEK 28 million).
“This investment is an important validation of both the technology and the team behind HAGA.BIO,” says Martina Banyay, KI Incubator Business Advisor for HAGABIO.
We are proud to see HAGA.BIO continue its growth journey and look forward to following the company’s progress as it advances innovative solutions at the intersection of research, biomarker discovery and clinical implementation.